Blog
RSS FeedPosted by Michael Wonder on 24 Feb 2021
Antengene announces new drug application for ATG-010 (selinexor) granted priority review by China's NMPA
23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...
Posted by Michael Wonder on 23 Feb 2021
The BCMA CAR-T co-developed by Innovent and IASO was granted breakthrough therapy designation by the NMPA for the treatment of relapsed/refractory multiple myeloma
22 February 2021 - Innovent Biologics today jointly announce that the Center for Drug Evaluation of China's National Medical Products Administration ...
Posted by Michael Wonder on 20 Feb 2021
Junshi Biosciences announces acceptance by the NMPA of supplemental new drug application for toripalimab combined with chemotherapy for the first-line treatment of nasopharyngeal carcinoma
19 February 2021 - Third sNDA for toripalimab in China. ...
Posted by Michael Wonder on 04 Feb 2021
Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab) by China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for non-squamous non-small cell lung cancer
3 February 2021 - Innovent Biologics and Eli Lilly today jointly announced that the National Medical Products Administration of China has ...
Posted by Michael Wonder on 04 Feb 2021
Bayer receives approval for Nubeqa in China for the treatment of men with non-metastatic castration-resistant prostate cancer
3 February 2021 - The Chinese National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide) for the treatment of patients with ...
Posted by Michael Wonder on 04 Feb 2021
Astellas' Xospata (gilteritinib) receives conditional approval by China's National Medical Products Administration for relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
3 February 2021 - Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings. ...
Posted by Michael Wonder on 04 Feb 2021
Forxiga approved in China for heart failure
4 February 2021 - Forxiga is the first SGLT2 inhibitor approved in China for heart failure with reduced ejection fraction in ...
Posted by Michael Wonder on 26 Jan 2021
Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma
26 January 2021 - Symbicort Turbuhaler becomes the first dual-combination therapy approved in China for mild, moderate and severe asthma ...
Posted by Michael Wonder on 15 Jan 2021
China National Medical Products Administration approves tislelizumab in combination with chemotherapy in first-line advanced squamous non-small cell lung cancer
13 January 2021 - BeiGene today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products ...
Posted by Michael Wonder on 13 Jan 2021
Innovent announces NMPA acceptance of a supplemental new drug application for Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab injection) as first-line therapy in hepatocellular carcinoma
12 January 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental ...
Posted by Michael Wonder on 30 Dec 2020
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List
28 December 2020 - Zai Lab today announced that Zejula has been included in the updated National Reimbursement Drug List released ...
Posted by Michael Wonder on 30 Dec 2020
BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List
27 December 2020 - Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor Brukinsa (zanubrutinib) are included in the National Reimbursement Drug List ...
Posted by Michael Wonder on 30 Dec 2020
Junshi Biosciences announces inclusion of toripalimab in the China National Reimbursement Drug List
29 December 2020 - Junshi Biosciences is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug ...
Posted by Michael Wonder on 09 Dec 2020
BeiGene announces the approval in China of Blincyto (blinatumomab) for injection for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
7 December 2020 - BeiGene today announced that the China NMPA has approved Blincyto (blinatumomab) for injection for the treatment of ...
Posted by Michael Wonder on 23 Nov 2020
BeiGene announces the approval of Xgeva (denosumab) in China for the prevention of skeletal-related events in patients with bone metastases from solid tumours and in patients with multiple myeloma
19 November 2020 - BeiGene today announced that the China NMPA has approved Xgeva (denosumab) for the prevention of skeletal-related events ...